RA Capital Management 13F holdings, Q4 2020
Holdings as of December 31, 2020 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 82 US equity positions worth $7.2bn in its Q4 2020 13F filing. The largest position was ASND at 13.7% of the reported book, followed by TGTX and NVAX. Against the Q3 2020 filing, it opened 12 new positions, added to 4 and reduced 9 among the top 50 holdings.
What did RA Capital Management own in Q4 2020? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2020 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 13.7% | $978.2m | 5,865,338 | -1% | reduced |
| 2 | TGTX TG THERAPEUTICS INC | Healthcare | 6.3% | $451.8m | 8,685,471 | -2% | reduced |
| 3 | NVAX NOVAVAX INC | Healthcare | 5.9% | $422.5m | 3,788,564 | 216% | added |
| 4 | NKTX NKARTA INC | Healthcare | 4.8% | $344.5m | 5,605,129 | 0% | held |
| 5 | FORMA THERAPEUTICS HLDGS INC | 4.4% | $314.5m | 9,011,651 | 0% | held | |
| 6 | ARVN ARVINAS INC | Healthcare | 4.4% | $311.9m | 3,672,872 | 0% | held |
| 7 | CHEMOCENTRYX INC | 4.1% | $295.8m | 4,776,548 | -1% | reduced | |
| 8 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 3.1% | $224.3m | 5,368,451 | – | new |
| 9 | ITEOS THERAPEUTICS INC | 2.1% | $149.4m | 4,417,258 | 0% | held | |
| 10 | KINNATE BIOPHARMA INC | 2.0% | $142.9m | 3,593,052 | – | new | |
| 11 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.9% | $134.9m | 1,655,447 | -19% | reduced |
| 12 | KROS KEROS THERAPEUTICS INC | Healthcare | 1.8% | $132.3m | 1,875,000 | 0% | held |
| 13 | PHAT PHATHOM PHARMACEUTICALS INC | 1.8% | $127.1m | 3,825,008 | 0% | held | |
| 14 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.7% | $124.2m | 4,179,067 | -19% | reduced |
| 15 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 1.7% | $124.2m | 4,557,867 | – | new |
| 16 | IMMUNOGEN INC | 1.7% | $118.8m | 18,417,458 | 162% | added | |
| 17 | RCKT ROCKET PHARMACEUTICALS INC COM | Healthcare | 1.6% | $117.1m | 2,136,081 | – | new |
| 18 | 89BIO INC | 1.6% | $115.4m | 4,736,214 | 0% | held | |
| 19 | ZOGENIX INC | 1.5% | $106.9m | 5,345,631 | -3% | reduced | |
| 20 | PMVP PMV PHARMACEUTICALS INC | 1.5% | $105.2m | 1,710,265 | 0% | held | |
| 21 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.4% | $103.4m | 2,150,404 | – | new |
| 22 | ADVERUM BIOTECHNOLOGIES INC | 1.4% | $103.0m | 9,502,383 | 1% | added | |
| 23 | MGNX MACROGENICS INC | Healthcare | 1.4% | $100.0m | 4,375,217 | 0% | held |
| 24 | PCVX VAXCYTE INC | Healthcare | 1.4% | $98.6m | 3,710,699 | -30% | reduced |
| 25 | IGM BIOSCIENCES INC | 1.2% | $86.8m | 982,723 | 0% | held | |
| 26 | BLACK DIAMOND THERAPEUTICS INC | 1.2% | $83.0m | 2,589,904 | 0% | held | |
| 27 | SPRY SILVERBACK THERAPEUTICS INC | Healthcare | 1.1% | $80.7m | 1,742,186 | – | new |
| 28 | TRILLIUM THERAPEUTICS INC | 1.1% | $77.8m | 5,290,481 | -14% | reduced | |
| 29 | SLDB SOLID BIOSCIENCES INC | 1.1% | $75.6m | 9,976,569 | 118% | added | |
| 30 | KALA PHARMACEUTICALS INC | 1.0% | $73.7m | 10,874,613 | 0% | held | |
| 31 | FPRX FIVE PRIME THERAPEUTICS INC | 1.0% | $72.9m | 4,285,161 | – | new | |
| 32 | INHIBRX INC | 1.0% | $70.2m | 2,129,003 | 0% | held | |
| 33 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.9% | $67.8m | 2,408,292 | 0% | held |
| 34 | CRIS CURIS INC | Healthcare | 0.9% | $63.1m | 7,707,790 | – | new |
| 35 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 0.9% | $61.2m | 7,775,207 | 0% | held |
| 36 | CRDF CARDIFF ONCOLOGY INC | 0.8% | $59.2m | 3,290,000 | 0% | held | |
| 37 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.8% | $58.9m | 2,805,045 | 0% | held |
| 38 | CNST CONSTELLATION PHARMCETICLS INC | 0.7% | $53.4m | 1,852,746 | – | new | |
| 39 | PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC | Healthcare | 0.7% | $51.6m | 1,987,997 | – | new |
| 40 | GERN GERON CORP | Healthcare | 0.7% | $47.9m | 30,126,299 | 0% | held |
| 41 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.6% | $46.0m | 2,118,212 | 0% | held |
| 42 | CCCC C4 THERAPEUTICS INC | Healthcare | 0.6% | $45.6m | 1,377,569 | – | new |
| 43 | AKOUOS INC | 0.6% | $45.2m | 2,281,249 | 0% | held | |
| 44 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.6% | $41.6m | 1,000,000 | 0% | held |
| 45 | INOZYME PHARMA INC | 0.6% | $41.4m | 2,003,653 | 0% | held | |
| 46 | ORCHARD THERAPEUTICS PLC | 0.6% | $41.2m | 12,315,213 | 0% | held | |
| 47 | ARDX ARDELYX INC | Healthcare | 0.6% | $39.9m | 6,163,086 | -2% | reduced |
| 48 | CEREVEL THERAPEUTICS HLDNG INC | 0.5% | $36.5m | 2,200,000 | – | new | |
| 49 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.5% | $32.8m | 1,165,184 | 0% | held |
| 50 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 0.5% | $32.4m | 1,515,151 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.